FluGen announced today that it closed a $12 million Series A financing round.

According to a release, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board, Knox LLC and FluGen’s existing investors participated in the round.

The company will use the funds to continue its development of REDEE FLU™, a vaccine that can activate a diverse immune response to protect against all strains of influenza.

FluGen also announced that it has added Inviragen Co-Founder Dan Stinchcomb, Ph.D. and Aviron Co-Founder C. Boyd Clarke to its Board of Directors.